ABN202 (αTROP2) / Abion - LARVOL DELTA

ABN202, a TROP2-targeted IFN-β mutein fusion protein, overcomes ADC resistance and elicits durable CD8⁺ T cell-dependent antitumor immunity (AACR 2026) - "ABN202 overcomes resistance to TROP2-targeted ADCs and demonstrates greater antitumor activity than an ADC plus anti-PD-1 combination in preclinical models. By inducing durable CD8⁺ T cell-mediated immunity, ABN202 offers a promising therapeutic strategy for patients with TROP2-positive solid tumors who have failed standard ADC-based treatments."

ADC • Late-breaking abstract • Breast Cancer • Oncology • Solid Tumor • CD8 • IFNAR1 • IFNB1 • TACSTD2

ABN202 (αTROP2), a sacituzumab-interferon-beta mutein fusion protein: a novel approach beyond antibody-drug conjugate therapeutics in ADC-naïve and ADC-refractory cancers (AACR 2025) - "TROP2-targeting antibody-drug conjugates (ADCs) such as Sacituzumab-govitecan (SG) and Datopotamab deruxtecan (Dato-DXd) demonstrated promising clinical efficacy in patients with TROP2-positive cancers. The preclinical toxicity profiles of SG, Dato-DXd, and ABN202 (αTROP2) were evaluated using human immune cells and hIFNAR KI mouse models.In conclusion, ABN202 (αTROP2) demonstrated potent anti-cancer efficacy and a tolerable safety profile compared to SG and Dato-DXd. Our findings suggest that ABN202 (αTROP2) represents a novel therapeutic approach beyond ADCs for both ADC-naïve and ADC-refractory cancers."

ADC • Breast Cancer • Hormone Receptor Breast Cancer • Hormone Receptor Positive Breast Cancer • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • Triple Negative Breast Cancer • IFNAR1 • IFNB1

ABN202 (αTROP2): A TROP2-Targeting IFN-β Mutein Fusion Protein with Retained Activity in Acidic Tumor Microenvironments and Reduced Toxicity for an Improved Therapeutic Window (SITC 2025) - "In xenograft and hIFNAR KI mouse models, ABN202 showed robust anti-tumor efficacy with favorable toxicity profiles.Conclusions ABN202 (αTROP2) demonstrates potent anti-tumor efficacy in acidic tumor microenvironments, with an improved preclinical toxicity profile compared to other type I IFNs. This balance between efficacy and safety expands the therapeutic window, supporting its potential as a best-in-class type I IFN-based therapeutic."

Biomarker • Tumor microenvironment • Oncology • IFNA1 • IFNAR1 • IFNB1